Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas
Abstract Angiogenesis is a key event in the progression of malignant gliomas. The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme. Tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation, migration, reor...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical neuroscience 2009-09, Vol.16 (9), p.1119-1130 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1130 |
|---|---|
| container_issue | 9 |
| container_start_page | 1119 |
| container_title | Journal of clinical neuroscience |
| container_volume | 16 |
| creator | Wong, Michael L.H Prawira, Amy Kaye, Andrew H Hovens, Christopher M |
| description | Abstract Angiogenesis is a key event in the progression of malignant gliomas. The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme. Tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation, migration, reorganisation of extracellular matrix and tube formation. These processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors. Angiogenesis inhibitors have been developed to interrupt the angiogenic process at the growth factor, receptor tyrosine kinase and intracellular kinase levels. Other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels. Most anti-angiogenic therapies for malignant gliomas are in Phase I/II trials and only modest efficacies are reported for monotherapies. The greatest potential for angiogenesis inhibitors may lie in their ability to combine safely with chemotherapy and radiotherapy. |
| doi_str_mv | 10.1016/j.jocn.2009.02.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67522680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0967586809001635</els_id><sourcerecordid>67522680</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-d5cbdecda2b485fd1c95b79465acce9080284ba6aa054004a5aba473c04102763</originalsourceid><addsrcrecordid>eNqFkU2L1TAUhoMoznX0D7iQrty1nqRJ2ooIMvgxMODC6zqcpufeSW2Sa9MK8-9NuRcEF7o6i_O87-J5GXvJoeLA9ZuxGqMNlQDoKhBVPo_YjqtalEKr-jHbQaebUrW6vWLPUhohE7KGp-yKd0ppXssd2-9XH9e5wHB08UiBkktvi9slFZ7sPQaXfP4NxXJPM55oXZwtnD9NzuLiYkiFC4XHyR0DhqU4Ti56TM_ZkwNOiV5c7jX7_unj_uZLeff18-3Nh7vSSglLOSjbD2QHFL1s1WHgtlN900mt0FrqoAXRyh41IigJIFFhj7KpLUgOotH1NXt97j3N8edKaTHeJUvThIHimoxulBC6hf-CAhrOQakMijNo55jSTAdzmp3H-cFwMJt0M5pNutmkGxAmnxx6dWlfe0_Dn8jFcgbenQHKMn45mk2yjoKlwc1kFzNE9-_-93_F7eRCXmD6QQ-UxrxfyJoNNykHzLdt9m116CA31qr-DbNqqL8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20711055</pqid></control><display><type>article</type><title>Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Wong, Michael L.H ; Prawira, Amy ; Kaye, Andrew H ; Hovens, Christopher M</creator><creatorcontrib>Wong, Michael L.H ; Prawira, Amy ; Kaye, Andrew H ; Hovens, Christopher M</creatorcontrib><description>Abstract Angiogenesis is a key event in the progression of malignant gliomas. The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme. Tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation, migration, reorganisation of extracellular matrix and tube formation. These processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors. Angiogenesis inhibitors have been developed to interrupt the angiogenic process at the growth factor, receptor tyrosine kinase and intracellular kinase levels. Other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels. Most anti-angiogenic therapies for malignant gliomas are in Phase I/II trials and only modest efficacies are reported for monotherapies. The greatest potential for angiogenesis inhibitors may lie in their ability to combine safely with chemotherapy and radiotherapy.</description><identifier>ISSN: 0967-5868</identifier><identifier>EISSN: 1532-2653</identifier><identifier>DOI: 10.1016/j.jocn.2009.02.009</identifier><identifier>PMID: 19556134</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Angiogenesis ; Angiogenesis Inhibitors - pharmacology ; Angiogenesis Inhibitors - therapeutic use ; Animals ; Brain Neoplasms - drug therapy ; Brain Neoplasms - pathology ; Clinical trials ; Glioma ; Glioma - blood supply ; Glioma - drug therapy ; Glioma - pathology ; Humans ; Neoplasms - blood supply ; Neoplasms - drug therapy ; Neoplasms - pathology ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - pathology ; Neovascularization, Pathologic - physiopathology ; Neurology ; Regional Blood Flow - drug effects</subject><ispartof>Journal of clinical neuroscience, 2009-09, Vol.16 (9), p.1119-1130</ispartof><rights>2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-d5cbdecda2b485fd1c95b79465acce9080284ba6aa054004a5aba473c04102763</citedby><cites>FETCH-LOGICAL-c440t-d5cbdecda2b485fd1c95b79465acce9080284ba6aa054004a5aba473c04102763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jocn.2009.02.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19556134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Michael L.H</creatorcontrib><creatorcontrib>Prawira, Amy</creatorcontrib><creatorcontrib>Kaye, Andrew H</creatorcontrib><creatorcontrib>Hovens, Christopher M</creatorcontrib><title>Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas</title><title>Journal of clinical neuroscience</title><addtitle>J Clin Neurosci</addtitle><description>Abstract Angiogenesis is a key event in the progression of malignant gliomas. The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme. Tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation, migration, reorganisation of extracellular matrix and tube formation. These processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors. Angiogenesis inhibitors have been developed to interrupt the angiogenic process at the growth factor, receptor tyrosine kinase and intracellular kinase levels. Other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels. Most anti-angiogenic therapies for malignant gliomas are in Phase I/II trials and only modest efficacies are reported for monotherapies. The greatest potential for angiogenesis inhibitors may lie in their ability to combine safely with chemotherapy and radiotherapy.</description><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - pathology</subject><subject>Clinical trials</subject><subject>Glioma</subject><subject>Glioma - blood supply</subject><subject>Glioma - drug therapy</subject><subject>Glioma - pathology</subject><subject>Humans</subject><subject>Neoplasms - blood supply</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Neovascularization, Pathologic - physiopathology</subject><subject>Neurology</subject><subject>Regional Blood Flow - drug effects</subject><issn>0967-5868</issn><issn>1532-2653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2L1TAUhoMoznX0D7iQrty1nqRJ2ooIMvgxMODC6zqcpufeSW2Sa9MK8-9NuRcEF7o6i_O87-J5GXvJoeLA9ZuxGqMNlQDoKhBVPo_YjqtalEKr-jHbQaebUrW6vWLPUhohE7KGp-yKd0ppXssd2-9XH9e5wHB08UiBkktvi9slFZ7sPQaXfP4NxXJPM55oXZwtnD9NzuLiYkiFC4XHyR0DhqU4Ti56TM_ZkwNOiV5c7jX7_unj_uZLeff18-3Nh7vSSglLOSjbD2QHFL1s1WHgtlN900mt0FrqoAXRyh41IigJIFFhj7KpLUgOotH1NXt97j3N8edKaTHeJUvThIHimoxulBC6hf-CAhrOQakMijNo55jSTAdzmp3H-cFwMJt0M5pNutmkGxAmnxx6dWlfe0_Dn8jFcgbenQHKMn45mk2yjoKlwc1kFzNE9-_-93_F7eRCXmD6QQ-UxrxfyJoNNykHzLdt9m116CA31qr-DbNqqL8</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Wong, Michael L.H</creator><creator>Prawira, Amy</creator><creator>Kaye, Andrew H</creator><creator>Hovens, Christopher M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20090901</creationdate><title>Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas</title><author>Wong, Michael L.H ; Prawira, Amy ; Kaye, Andrew H ; Hovens, Christopher M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-d5cbdecda2b485fd1c95b79465acce9080284ba6aa054004a5aba473c04102763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - pathology</topic><topic>Clinical trials</topic><topic>Glioma</topic><topic>Glioma - blood supply</topic><topic>Glioma - drug therapy</topic><topic>Glioma - pathology</topic><topic>Humans</topic><topic>Neoplasms - blood supply</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Neovascularization, Pathologic - physiopathology</topic><topic>Neurology</topic><topic>Regional Blood Flow - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Michael L.H</creatorcontrib><creatorcontrib>Prawira, Amy</creatorcontrib><creatorcontrib>Kaye, Andrew H</creatorcontrib><creatorcontrib>Hovens, Christopher M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Michael L.H</au><au>Prawira, Amy</au><au>Kaye, Andrew H</au><au>Hovens, Christopher M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas</atitle><jtitle>Journal of clinical neuroscience</jtitle><addtitle>J Clin Neurosci</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>16</volume><issue>9</issue><spage>1119</spage><epage>1130</epage><pages>1119-1130</pages><issn>0967-5868</issn><eissn>1532-2653</eissn><abstract>Abstract Angiogenesis is a key event in the progression of malignant gliomas. The presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme. Tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation, migration, reorganisation of extracellular matrix and tube formation. These processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors. Angiogenesis inhibitors have been developed to interrupt the angiogenic process at the growth factor, receptor tyrosine kinase and intracellular kinase levels. Other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels. Most anti-angiogenic therapies for malignant gliomas are in Phase I/II trials and only modest efficacies are reported for monotherapies. The greatest potential for angiogenesis inhibitors may lie in their ability to combine safely with chemotherapy and radiotherapy.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>19556134</pmid><doi>10.1016/j.jocn.2009.02.009</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0967-5868 |
| ispartof | Journal of clinical neuroscience, 2009-09, Vol.16 (9), p.1119-1130 |
| issn | 0967-5868 1532-2653 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67522680 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Angiogenesis Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use Animals Brain Neoplasms - drug therapy Brain Neoplasms - pathology Clinical trials Glioma Glioma - blood supply Glioma - drug therapy Glioma - pathology Humans Neoplasms - blood supply Neoplasms - drug therapy Neoplasms - pathology Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Neovascularization, Pathologic - physiopathology Neurology Regional Blood Flow - drug effects |
| title | Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A09%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumour%20angiogenesis:%20Its%20mechanism%20and%20therapeutic%20implications%20in%20malignant%20gliomas&rft.jtitle=Journal%20of%20clinical%20neuroscience&rft.au=Wong,%20Michael%20L.H&rft.date=2009-09-01&rft.volume=16&rft.issue=9&rft.spage=1119&rft.epage=1130&rft.pages=1119-1130&rft.issn=0967-5868&rft.eissn=1532-2653&rft_id=info:doi/10.1016/j.jocn.2009.02.009&rft_dat=%3Cproquest_cross%3E67522680%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20711055&rft_id=info:pmid/19556134&rft_els_id=S0967586809001635&rfr_iscdi=true |